Navigating Your Weight Loss Journey: Can You Take Omeprazole with Wegovy?

Last reviewed: July 3, 2026

Last updated: July 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Omeprazole is not listed as a contraindication or a flagged interaction on the Wegovy label, and the manufacturer's own pharmacokinetic testing found no clinically significant differences in semaglutide exposure when the two were given together — but "no known interaction" is not the same as "no reason to tell your prescriber," and the reason people ask this question at all is worth unpacking. The Wegovy prescribing information states plainly that no clinically significant differences in semaglutide pharmacokinetics were observed when used concomitantly with omeprazole. That is the direct answer. What follows is the context that makes it useful.

Why This Question Comes Up So Often

Reflux symptoms are common on semaglutide. In the Wegovy clinical program, gastroesophageal reflux disease was reported in 5% of participants, dyspepsia in 9%, and eructation in 7%, alongside nausea at 44%, diarrhea at 30%, vomiting at 24%, and constipation at 24%. Omeprazole, a proton pump inhibitor, is one of the most widely used treatments for reflux and is available both by prescription and over the counter.

So the overlap is not coincidental. A large number of people starting a GLP-1 medication develop upper gastrointestinal symptoms, reach for a familiar acid-suppressing drug, and then wonder whether they have just created a problem. It is a sensible instinct — and in this particular pairing, the pharmacology is reassuring.

What the Labels Actually Say About the Pairing

Wegovy's drug interactions section addresses oral medications generally: the medication delays gastric emptying and therefore has the potential to affect the absorption of concomitantly administered oral drugs. The manufacturer ran clinical pharmacology studies to test that concern against real drugs. Omeprazole was one of them, along with lisinopril, warfarin, metformin, digoxin, ethinyl estradiol, levonorgestrel, furosemide, and rosuvastatin. No clinically significant differences were observed with any of them. The one signal the label does highlight is levothyroxine, where total thyroxine exposure was increased by 33%.

The same finding appears on the oral semaglutide labeling. The Rybelsus prescribing information — for the tablet formulation of semaglutide co-formulated with the absorption enhancer SNAC, where absorption predominantly occurs in the stomach and might plausibly be more sensitive to acid suppression — also reports no clinically significant differences in semaglutide pharmacokinetics with concomitant omeprazole. That is a meaningful check, because it is the scenario where an interaction would have been most likely.

The Metabolic Reason There Is No Collision

These two drugs are cleared by completely different machinery. Omeprazole is extensively metabolized by the cytochrome P450 enzyme system — which is why its interaction profile centers on other CYP substrates. Semaglutide is not. Its primary route of elimination is metabolism following proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain, with excretion via urine and feces and roughly 3% of the dose excreted in urine as intact semaglutide.

Semaglutide also has very low potential to inhibit or induce CYP enzymes or to inhibit drug transporters. There is simply no shared pathway for the two to compete over. The theoretical concern with semaglutide and oral drugs is about absorption timing, not metabolism, and that concern was tested directly against omeprazole and did not materialize.

Where Gastric pH Does Matter — Just Not Here

Omeprazole's own labeling is candid that profound, long-lasting acid suppression can theoretically interfere with the absorption of drugs for which gastric pH is an important determinant. The Prilosec prescribing information names ketoconazole, ampicillin esters, iron salts, and erlotinib as having decreased absorption, and digoxin as having increased absorption.

Injectable semaglutide bypasses that question entirely — it is administered subcutaneously and never encounters gastric acid. And for the oral tablet, where the question is genuinely live, the interaction study still came back clean. The practical implication is that if you take other oral medications alongside both drugs, those medications are the ones worth reviewing, not the semaglutide.

The Conversation Still Belongs With Your Prescriber

Absence of a labeled interaction is a narrow finding. It says two molecules do not disturb each other's blood levels in a controlled study. It does not say that taking a proton pump inhibitor is the right response to your reflux symptoms, that those symptoms are actually reflux, or that long-term acid suppression carries no cost. Omeprazole's label carries warnings about bone fracture risk with long-term multiple-daily-dose therapy, hypomagnesemia with prolonged treatment, an association with Clostridioides difficile-associated diarrhea, and atrophic gastritis on long-term gastric biopsies.

There is also a diagnostic reason not to self-manage. Persistent upper abdominal pain on a GLP-1 medication is not automatically reflux. The Wegovy label carries warnings for acute pancreatitis, acute gallbladder disease, and severe gastrointestinal adverse reactions. Suppressing a symptom with an over-the-counter product can delay identifying which of those is actually happening. Tell whoever prescribes your semaglutide about every medication you take, including over-the-counter ones.

One Thing to Raise Before Any Procedure

Both semaglutide labels carry a warnings and precautions subsection on pulmonary aspiration during general anesthesia or deep sedation. The Wegovy label describes rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation, who had residual gastric contents despite reported adherence to preoperative fasting recommendations.

This matters in a reflux conversation because delayed gastric emptying is the shared mechanism. If you are scheduled for surgery, an endoscopy, or a dental procedure under sedation, your anesthesia team needs to know you are on a GLP-1 medication. That instruction comes from them and from your prescriber, not from an article.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Can you take omeprazole with Wegovy?

The Wegovy prescribing information reports that no clinically significant differences in semaglutide pharmacokinetics were observed when it was used concomitantly with omeprazole, and omeprazole is not listed as a contraindication. That said, whether a proton pump inhibitor is appropriate for your symptoms is a clinical judgment. Tell your prescriber about every medication you take, including over-the-counter products.

Does Wegovy cause acid reflux?

Gastroesophageal reflux disease was reported in 5% of participants in the Wegovy clinical program, with dyspepsia in 9% and eructation in 7%. The most common adverse reactions were nausea at 44%, diarrhea at 30%, vomiting at 24%, and constipation at 24%. Because semaglutide delays gastric emptying, upper gastrointestinal symptoms are common, particularly early in treatment.

Do I need to separate the timing of omeprazole and semaglutide?

The labeling does not specify any dose separation for omeprazole. The interaction studies were conducted with concomitant administration and found no clinically significant differences in semaglutide exposure, including for the oral tablet formulation where gastric absorption would make an interaction most plausible. Any timing instruction specific to you should come from your prescriber or pharmacist.

Why is levothyroxine singled out on the Wegovy label?

In a drug interaction study with the semaglutide tablet, levothyroxine exposure increased by 33%. Because semaglutide delays gastric emptying, it can alter how some oral drugs are absorbed, and levothyroxine was the one medication in the studied set where the effect was large enough to note. The label advises considering increased clinical or laboratory monitoring with concomitant oral medications.

Should I tell my anesthesiologist I take Wegovy?

Yes. The Wegovy label includes a warnings subsection on pulmonary aspiration during general anesthesia or deep sedation, citing rare postmarketing reports in patients on GLP-1 receptor agonists who had residual gastric contents despite reported adherence to preoperative fasting. Anyone scheduling surgery, endoscopy, or dental work under sedation should disclose GLP-1 use so the care team can plan accordingly.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.